JWH-262

JWH-262 is a synthetic cannabinoid that acts as a potent agonist at both the CB1 and CB2 receptors. It is part of the naphthoylindole family of compounds and was first synthesized by John W. Huffman and his team at Clemson University.

Chemical Structure and Properties

JWH-262 is chemically classified as a naphthoylindole, which is a subclass of synthetic cannabinoids. Its chemical structure consists of a 1-pentyl-3-(2,2,3,3-tetramethylcyclopropyl)indole core. The presence of the cyclopropyl group is a distinguishing feature that contributes to its binding affinity and selectivity for cannabinoid receptors.

Pharmacology

JWH-262 acts as a full agonist at both the CB1 and CB2 receptors, with a higher affinity for the CB2 receptor. This receptor selectivity is significant because CB1 receptors are primarily located in the central nervous system, while CB2 receptors are found in peripheral tissues and are associated with immune function.

Mechanism of Action

The mechanism of action of JWH-262 involves the activation of cannabinoid receptors, which are part of the endocannabinoid system. Upon binding to these receptors, JWH-262 mimics the effects of naturally occurring endocannabinoids, leading to various physiological and psychoactive effects.

Legal Status

The legal status of JWH-262 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids and "designer drugs."

Potential Effects and Risks

The use of JWH-262, like other synthetic cannabinoids, can lead to a range of effects, including euphoria, altered perception, and relaxation. However, it can also cause adverse effects such as anxiety, paranoia, tachycardia, and in severe cases, psychosis. The lack of regulation and quality control in the production of synthetic cannabinoids increases the risk of harmful side effects.

Research and Applications

Research on JWH-262 and similar compounds is primarily focused on understanding the endocannabinoid system and developing potential therapeutic agents. However, due to its psychoactive properties and potential for abuse, its use is limited to controlled laboratory settings.

Also see

• Synthetic cannabinoids
• Cannabinoid receptor
• John W. Huffman
• Naphthoylindole
• Endocannabinoid system